CAS: 1453099-83-6; Tas-119

主要参考文献

1: Miura A, Sootome H, Fujita N, Suzuki T, Fukushima H, Mizuarai S, Masuko N, Ito K, Hashimoto A, Uto Y, Sugimoto T, Takahashi H, Mitsuya M, Hirai H. TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways. Invest New Drugs. 2021 Jun;39(3):724-735. doi: 10.1007/s10637-020-01019-9. Epub 2021 Jan 6. 124(2):391-398. doi: 10.1038/s41416-020-01100-3. Epub 2020 Oct 6.
3: Sootome H, Miura A, Masuko N, Suzuki T, Uto Y, Hirai H. Aurora A Inhibitor TAS-119 Enhances Antitumor Efficacy of Taxanes In Vitro and In Vivo: Preclinical Studies as Guidance for Clinical Development and Trial Design. Mol Cancer Ther. 2020 Oct;19(10):1981-1991. doi: 10.1158/1535-7163.MCT-20-0036. Epub 2020 Aug 11.

合成参考文献

参考文献:10.1007/s10637-020-01019-9
摘要:Miura A, Sootome H, Fujita N, Suzuki T, Fukushima H, Mizuarai S, Masuko N, Ito K, Hashimoto A, Uto Y, Sugimoto T, Takahashi H, Mitsuya M, Hirai H. TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways. Invest New Drugs. 2021 Jun;39(3):724–35. doi: 10.1007/s10637-020-01019-9.